How to Lower Triglycerides: Doses, Diet Levers, and What the Evidence Shows
A triglyceride number over 150 rarely arrives as a shock diagnosis. It usually turns up on a routine lipid panel, next to cholesterol readings you have seen for years, with a vague instruction to eat better. That advice is not wrong, just too general to act on. The changes that actually move triglycerides are more specific, and the supplement most people already take is often dosed too low to matter.
This guide answers how to lower triglycerides by putting the evidence in order: what the number means, why it shifted since your last test, and the food, habit and supplement levers ranked by how well they hold up in trials.
What Your Triglyceride Number Actually Means
Triglycerides are the main form of stored fat in your body, and they also travel through the bloodstream inside particles called VLDL. A triglyceride reading measures how much of that fat was circulating when your blood was drawn.
Triglycerides are not the same as cholesterol. Both appear on a standard lipid panel and both are tied to cardiovascular risk, but they are different molecules that respond to different inputs (1).
Guideline bodies have settled on four bands, and the band decides how much attention the number deserves:
| Tier | Range | What it usually signals |
|---|---|---|
| Normal | Below 150 mg/dL | The range linked with the lowest cardiovascular risk in guideline consensus. |
| Borderline | 150 to 199 mg/dL | Mild elevation, common and often responsive to food, alcohol and weight changes. |
| High | 200 to 499 mg/dL | A level guideline bodies treat as hypertriglyceridemia, where cardiovascular risk gets more attention. |
| Very high | 500 mg/dL and above | The level where the main short-term concern shifts to pancreatitis risk. |
For most adults the target is below 150 mg/dL. A reading of 150 to 199 is a nudge; above 200 the levers below matter more; at 500 or above the conversation changes entirely. For the wider cardiovascular picture, see the Heart and Circulation resource.
Why Your Number Moved: Fasting, Timing, and the Test Itself
Two panels weeks apart can disagree, and the reason is often the test, not your body. Triglycerides rise after you eat, and across four large prospective studies the biggest average swing from normal food intake was about 26 mg/dL (0.3 mmol/L) (12). If one panel was fasting and the other was not, part of the gap is arithmetic.
Non-fasting triglycerides are actually better than fasting ones at predicting cardiovascular risk, and some countries are moving their guidelines toward non-fasting sampling for that reason (12). A higher non-fasting reading is not automatically a wrong one. Before you change anything, check whether the two tests were taken under the same conditions.
The Food Levers, In Evidence Order
Diet is the first lever, not the last, but the food changes do not carry equal weight. In each case the mechanism runs through the liver, which turns excess sugar and alcohol into triglyceride-rich VLDL. If liver and metabolic context interests you, our guide to fatty liver support covers it.
Added Sugar and Refined Starch
Added sugar and refined starch are the top food lever, and the National Lipid Association puts restricting them first for elevated triglycerides (6). This is the lever most people underrate after they have already cut fat and left the sugar. The liver does not need dietary fat to make triglycerides; excess sugar and starch are enough. If cutting sugar is the hardest part to hold, our guide to taming sugar cravings helps.
Alcohol
Alcohol sits second. At the population level it shows a J-shaped relationship with triglycerides, but the picture is worse when body weight is already high, because obesity exaggerates alcohol-related triglyceride elevation and the pancreatitis risk that follows (7). Alcohol raises triglycerides by increasing VLDL secretion, impairing the breakdown of fat particles and pushing more free fatty acids to the liver (7). For anyone with high triglycerides, the guidance is to reduce or stop.
Carbohydrate Load
Total carbohydrate load matters too. In a randomized controlled feeding trial, 164 people were first brought to a 10 to 14 percent weight loss, then assigned to 20, 40 or 60 percent carbohydrate for 20 weeks (8). The low-carbohydrate arm improved triglycerides, HDL cholesterol, lipoprotein(a) and an insulin-resistance score, and LDL cholesterol did not differ between the diets (8). The size of the carbohydrate share, not just the type, did real work in that trial.
Weight, Even a Little
Weight loss helps, and it does not have to be dramatic. Improvement in triglycerides and blood sugar begins with small amounts of loss and grows with more, and a modest 5 to 10 percent reduction is associated with better blood pressure and HDL cholesterol too (10). The useful target is health gains, not a number on the scale.
A plant-based shift reliably improves cholesterol but does not reliably fix triglycerides. In a meta-analysis of 30 randomized trials, vegetarian and vegan diets lowered total cholesterol, LDL cholesterol and apolipoprotein B, with no significant difference in triglyceride levels (18). More plants is a good idea for other reasons, but do not expect it to move this marker alone.
The Habits Nobody Ranks High Enough
Movement is the habit with the clearest measurement, and the honest size of it is modest. Across 148 randomized controlled trials and 8,673 participants, exercise training lowered triglycerides by a mean of about 8 mg/dL, and combined aerobic plus resistance training was optimal (9). The authors call the effects on all five lipid markers modest (9).
About 8 mg/dL will not take a high reading to normal on its own. That does not make exercise pointless. It works alongside the other levers, improves the weight and blood-sugar factors that drive triglycerides, and carries low risk.
Blood sugar is a large part of that picture, since insulin resistance sits behind a lot of elevated readings. If yours runs high, our overview of blood sugar support covers the terrain.
Do Supplements Help? The Evidence, Graded
Supplements are the third lever here, behind food and weight, and only one has strong evidence. Grading them honestly is more useful than treating the whole aisle as either hero or villain.
Omega-3: The One With the Best Evidence
Omega-3 has the best supporting evidence for this marker. The American Heart Association has recommended 2 to 4 grams per day of combined EPA and DHA for high triglycerides since 2002, a position that has not changed (1). Above 3 grams per day total EPA and DHA, the advisory treats the dose as pharmacological, doing drug-like work rather than acting as a nutrient (1).
That range is far above what most people get. A capsule sold as "1000 mg fish oil" typically contains roughly 300 mg of actual EPA and DHA, because the rest is other oil, so reaching even the low end of the research range is the difference between one capsule and several. Closing that gap is a matter of omega-3 concentration per softgel, not bottle size. For help reading those labels, see our fish oil buying guide.
The dose-response relationship supports the range. In a meta-analysis of 90 randomized trials covering 72,598 participants, the link between omega-3 intake and triglycerides was roughly linear and most evident in people with high lipids or excess weight taking more than 2 grams per day (4).
EPA and DHA are not interchangeable for this purpose, and most articles skip that. At 4 grams per day, combined EPA and DHA lowered triglycerides by 30 percent or more but also raised LDL cholesterol in people with very high triglycerides, while EPA alone did not raise LDL cholesterol in that group (1). If you want to lean on the EPA side of that split, an EPA-dominant fish oil is the more direct route. The form a capsule comes in also matters for absorption, which our guide to choosing a fish oil form explains.
The cardiovascular story is genuinely unsettled, so both trials belong here. In REDUCE-IT, icosapent ethyl, an EPA-only prescription at 4 grams per day in statin-treated high-risk patients, was associated with a 25 percent reduction in major adverse cardiovascular events (2). In STRENGTH, 4 grams per day of an EPA and DHA formulation in 13,078 statin-treated high-risk patients did not reduce the primary cardiovascular outcome, and the trial was stopped (3). The lipid lowering is consistent; the event reduction is not. For the wider picture, see our guide to omega-3 benefits.
One safety point comes up often: across 8 clinical studies and more than 600 patients, including people on blood thinners, no evidence of increased bleeding risk was found, and the authors support safe use at short-term doses up to 10 grams per day of EPA and DHA (15). If you take a blood thinner or have surgery planned, that is still a conversation for your clinician.
Niacin: It Moves the Number and Still Failed
Niacin is the clearest cautionary tale in the aisle. It does lower triglycerides, yet it failed to improve outcomes and produced real harm along the way. In HPS2-THRIVE, adding extended-release niacin with laropiprant at 2000/40 mg per day to intensive statin therapy in 25,673 high-risk patients produced no cardiovascular benefit over a median of 3.9 years (13). It was associated with new-onset diabetes (hazard ratio 1.32), serious bleeding (1.38) and serious infection (1.22) (13). Lowering the number and improving health are not the same thing.
Turmeric, Berberine, and the Rest of the Aisle
Curcumin, the active compound in turmeric, has the most published data of the popular metabolic supplements, and the data is weak. A GRADE-assessed analysis of 64 randomized trials found small, statistically significant changes in triglycerides, a weighted mean difference of about 6.7 mg/dL, but the authors rated the evidence certainty low to very low and said the findings need caution (14).
Berberine, garlic and the fiber-based options circulate as triglyceride fixes too. They have no high-certainty lipid outcome data in the sources behind this article, so they are unproven for this marker. Coconut oil is the clearest aisle favorite that backfires: across 16 trials it raised LDL cholesterol by about 10 mg/dL versus non-tropical vegetable oils, with no benefit to body fat or blood sugar (17).
What I Would Skip
Skip any proprietary metabolic blend with no dose on the label, since an unlisted dose cannot be compared to anything. Skip megadose niacin, given the HPS2-THRIVE results.
Fibrates are worth naming only to keep them in their lane. They are prescription drugs, studied in populations like the 9,795 people with type 2 diabetes in the FIELD trial (16), and they are a clinician's decision, not a shelf decision.
Before You Blame Your Diet: Causes You Did Not Choose
Not every high reading is a diet problem. Most triglyceride elevation comes from a mix of small genetic variants plus environmental factors, and the common secondary causes are obesity, uncontrolled diabetes and alcohol misuse (5). Those usually deserve attention before anything on a shelf.
Medications are the cause people miss most. A long list of common prescriptions can raise triglycerides, including oral estrogen, corticosteroids, beta-blockers, thiazide diuretics, retinoids, antipsychotics, antiseizure drugs, cyclosporine and tacrolimus (5). None is a reason to quit a prescription on your own.
The actionable step is a question, not a change. If your triglycerides jumped and your habits did not, ask your clinician or pharmacist to review your medication list. Sometimes the answer is a different drug in the same class, a decision a prescriber should make with you.
When 500 Is Not a Lifestyle Problem
At 500 mg/dL and above, the picture changes. The primary objective at this level is reducing the risk of pancreatitis, and reducing cardiovascular risk drops to second place (6). Hypertriglyceridemia is the third most common cause of acute pancreatitis, and those cases tend to be more severe, more often involving persistent organ failure (11).
The goal at 500 is not a smaller number for its own sake; it is staying out of the hospital, and the tools at that level include prescription options that belong with a clinician (6). This is not a supplement question. If your reading is 500 or above, the next call is to your doctor, and the lifestyle levers here are what you do alongside that care.
Frequently Asked Questions
What is a normal triglyceride level?
A normal reading is below 150 mg/dL, which is the range linked with the lowest cardiovascular risk in guideline consensus. A reading of 150 to 199 is borderline, 200 to 499 is high, and 500 or above is very high.
How long does it take to lower triglycerides?
The food, alcohol and weight levers can move the number, though how quickly varies from person to person. Ask your clinician when to recheck, so the next sample is taken under the same conditions as the last.
Does fish oil lower triglycerides, and how much do I need?
Yes, omega-3 has the best evidence of any supplement for this marker. The American Heart Association has recommended 2 to 4 grams per day of combined EPA and DHA since 2002, and doses above 3 grams per day are treated as pharmacological (1). A standard 1000 mg fish oil capsule holds only about 300 mg of actual EPA and DHA, so label arithmetic decides how much you are really getting.
Can I lower triglycerides without medication?
Often, yes, especially in the borderline and high bands. Cutting added sugar, refined starch and alcohol, losing a modest amount of weight and adding regular movement can all move the number (6)(9)(10). At 500 mg/dL and above, where the goal is reducing the risk of pancreatitis, prescription treatment is the usual path (6).
Is high triglycerides the same as high cholesterol?
No. They are different fats measured on the same panel, and they respond to different things (1). A plant-based diet, for example, reliably lowers LDL cholesterol but does not significantly change triglycerides (18). It is possible to have one high and the other normal.
What raises triglycerides the most?
Added sugar and refined starch, alcohol, overall carbohydrate load and excess weight are the top contributors (6)(7)(8). Medications and conditions like uncontrolled diabetes can also raise the number on their own, which is why a sudden jump without a diet change is worth a medication review (5).
What We Recommend
Supplements are the third lever here, behind food and weight, and omega-3 is the only one with strong evidence for this marker. The practical question is whether a fish oil actually delivers enough EPA and DHA to matter, so these are the concentrated and EPA-forward options that make the research range reachable in a sensible number of softgels.
Integrative Therapeutics, Pure Omega Ultra HP 90 Softgels
1,085 mg of omega-3 (575 mg EPA, 425 mg DHA) in a single softgel, so the research range takes fewer capsules.
$69.25
XYMOGEN, Omega MonoPure 1300 EC 120 Softgels
A concentrated 1,300 mg omega-3 softgel in enteric-coated form, for reaching a research-range dose in fewer capsules.
$118.99
Nordic Naturals, ProOmega Cholesterol Support 180 Soft Gels
Concentrated omega-3 with 489 mg EPA and 336 mg DHA per serving, for a higher daily dose in fewer softgels.
$84.00
Nordic Naturals, ProEPA Xtra Lemon 120 Soft Gels
EPA-dominant at 1,060 mg EPA and 260 mg DHA per serving.
$78.87
References
- Skulas-Ray AC, Wilson PWF, Harris WS, et al; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation. 2019. https://pubmed.ncbi.nlm.nih.gov/31422671/
- Bhatt DL, Steg PG, Miller M, et al; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 2019. https://pubmed.ncbi.nlm.nih.gov/30415628/
- Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020. https://pubmed.ncbi.nlm.nih.gov/33190147/
- Wang T, Zhang X, Zhou N, et al. Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association. 2023. https://pubmed.ncbi.nlm.nih.gov/37264945/
- Simha V. Management of hypertriglyceridemia. BMJ. 2020. https://pubmed.ncbi.nlm.nih.gov/33046451/
- Kirkpatrick CF, Sikand G, Petersen KS, et al. Nutrition interventions for adults with dyslipidemia: A Clinical Perspective from the National Lipid Association. Journal of Clinical Lipidology. 2023. https://pubmed.ncbi.nlm.nih.gov/37271600/
- Klop B, do Rego AT, Cabezas MC. Alcohol and plasma triglycerides. Current Opinion in Lipidology. 2013. https://pubmed.ncbi.nlm.nih.gov/23511381/
- Ebbeling CB, Knapp A, Johnson A, et al. Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia: a randomized controlled feeding trial. American Journal of Clinical Nutrition. 2022. https://pubmed.ncbi.nlm.nih.gov/34582545/
- Smart NA, Downes D, van der Touw T, et al. The Effect of Exercise Training on Blood Lipids: A Systematic Review and Meta-analysis. Sports Medicine. 2025. https://pubmed.ncbi.nlm.nih.gov/39331324/
- Ryan DH, Yockey SR. Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over. Current Obesity Reports. 2017. https://pubmed.ncbi.nlm.nih.gov/28455679/
- Yang AL, McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis. Pancreatology. 2020. https://pubmed.ncbi.nlm.nih.gov/32571534/
- Langsted A, Nordestgaard BG. Nonfasting versus fasting lipid profile for cardiovascular risk prediction. Pathology. 2019. https://pubmed.ncbi.nlm.nih.gov/30522787/
- Haynes R, Valdes-Marquez E, Hopewell JC, et al; HPS2-THRIVE Collaborative Group. Serious Adverse Effects of Extended-release Niacin/Laropiprant: Results From the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) Trial. Clinical Therapeutics. 2019. https://pubmed.ncbi.nlm.nih.gov/31447131/
- Dehzad MJ, Ghalandari H, Amini MR, Askarpour M. Effects of curcumin/turmeric supplementation on lipid profile: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Complementary Therapies in Medicine. 2023. https://pubmed.ncbi.nlm.nih.gov/37230418/
- Jeansen S, Witkamp RF, Garthoff JA, van Helvoort A, Calder PC. Fish oil LC-PUFAs do not affect blood coagulation parameters and bleeding manifestations: Analysis of 8 clinical studies with selected patient groups on omega-3-enriched medical nutrition. Clinical Nutrition. 2018. https://pubmed.ncbi.nlm.nih.gov/28427779/
- Keech A, Simes RJ, Barter P, et al; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet. 2005. https://pubmed.ncbi.nlm.nih.gov/16310551/
- Neelakantan N, Seah JYH, van Dam RM. The Effect of Coconut Oil Consumption on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Clinical Trials. Circulation. 2020. https://pubmed.ncbi.nlm.nih.gov/31928080/
- Koch CA, Kjeldsen EW, Frikke-Schmidt R. Vegetarian or vegan diets and blood lipids: a meta-analysis of randomized trials. European Heart Journal. 2023. https://pubmed.ncbi.nlm.nih.gov/37226630/
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
